AGRN and myocardial infarction: To date, a variety of pre-clinical studies have been conducted utilizing a broad range of ECM-based treatment strategies; including variations in ECM source [single ECM components (i.e. collagen, fibrin, hyaluronic acid, agrin, or fibronectin) or decellularized whole organ ECM (dECM)], animal model (mouse, rat or pig), type of myocardial injury (MI or ischemia/reperfusion injury), method for administration (cardiac patches, intramyocardial injections or osmotic pumps), and timing of the treatment (directly, hours or weeks after MI).